879127-21-6

Basic information

• Product Name: N-(3-AMINOPHENYL)CYCLOPROPANECARBOXAMIDE
• Synonyms: N-(3-AMINOPHENYL)CYCLOPROPANECARBOXAMIDE;N-(3-aminophenyl)cyclopropanecarboxamide(SALTDATA: FREE)
• CAS NO: 879127-21-6
• Molecular Formula: C₁₀H₁₂N₂O
• Molecular Weight: 176
• Mol File: 879127-21-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(3-AMINOPHENYL)CYCLOPROPANECARBOXAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3-AMINOPHENYL)CYCLOPROPANECARBOXAMIDE(879127-21-6)
• EPA Substance Registry System: N-(3-AMINOPHENYL)CYCLOPROPANECARBOXAMIDE(879127-21-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 879127-21-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(3-aminophenyl)cyclopropanecarboxamide is used as a building block for the synthesis of various drug substances and biologically active molecules. Its ability to serve as a versatile intermediate makes it a valuable component in the development of new medications.
Used in Organic Synthesis:
N-(3-aminophenyl)cyclopropanecarboxamide is utilized as a reagent in organic synthesis, contributing to the creation of a wide range of organic compounds for various applications.
Used in Medicinal Chemistry:
This chemical compound is also employed in medicinal chemistry, where it aids in the research and development of new pharmaceuticals and the enhancement of existing ones. Its unique properties make it an essential tool in drug discovery processes.

Upstream product

• 4531-79-7 3-nitro-N-phenylaniline 
• 99-09-2 3-nitro-aniline 
• 101946-39-8 N-(3-nitrophenyl) cyclopropanecarboxamide 

Downstream Products

• 879127-16-9 Aurora Kinase inhibitor III 
• 879127-07-8 EGFR Inhibitor 
• 899788-85-3 cyclopropanecarboxylic acid [3-(2-chloro-pyrimidin-4-ylamino)-phenyl]-amide 
• 879127-22-7 cyclopropanecarboxylic acid [3-(6-chloro-pyrimidin-4-ylamino)-phenyl]-amide 
• 1395923-09-7 C₂₅H₂₂N₂O₂ 
• 1395923-42-8 C₂₁H₂₂N₂O₂ 
• 899788-86-4 cyclopropanecarboxylic acid {3-[(6-chloro-pyrimidin-4-yl)-methyl-amino]-phenyl}-amide 

Relevant articles and documents

BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.

Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors

By combining the scaffolds of UI-125 and Sorafenib, a series of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine moiety were designed and synthesized as novel DFG-out B-RafV600E inhibitors. Among them, 20c-e, 20g and 21h displayed potent antiproliferative activities against melanoma A375 (B-RafV600E) cell lines with IC50 values of 3.190, 2.276, 1.856, 1.632 μM and 1.839 μM, respectively, comparable with the positive control Vemurafenib (IC50 Combining double low line 3.32 μM). Selected compounds were tested for the ERK inhibition in human melanoma A375 (B-RafV600E) and SK-MEL-2 (B-RafWT) cell lines by Western blot. The results revealed that our compounds inhibited the proliferation of melanoma A375 cells (B-RafV600E) through ERK pathway, without paradoxical activation of ERK in melanoma SK-MEL-2 cells (B-RafWT). Eventually, 20g and 21h were selected to confirm their inhibitory effects on tumor growth in A375 xenograft models in mice. Compound 20g exhibited equivalent antitumor efficacy in vivo (T/C Combining double low line 44.37%), compared to Sorafenib (T/C Combining double low line 37.35%), by 23-day repetitive administration of a single dose of 50 mg/kg without significant body weight loss.

Pyrrolo[3,2-b ]quinoxaline derivatives as types I1/2 and II Eph tyrosine kinase inhibitors: Structure-based design, synthesis, and in vivo validation

The X-ray crystal structures of the catalytic domain of the EphA3 tyrosine kinase in complex with two type I inhibitors previously discovered in silico (compounds A and B) were used to design type I1/2 and II inhibitors. Chemical synthesis of a

2, 4 -DIAMINOPYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS

The present invention relates to novel pyrimide derivatives of formula (I): that are useful as kinase inhibitors. More particularly, the present invention relates to novel pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders.

COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly di

Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library

The epidermal growth factor receptor (EGFR) tyrosine kinase was one of the first receptor tyrosine kinases to be targeted for drug development by the pharmaceutical industry due to its ubiquitous overexpression in a variety of tumors. Despite the validati